Impact of Oral Nutritional Supplementation and Dietary Counseling on Outcomes of Linear Catch-Up Growth in Indian Children Aged 3–6.9 Years: Findings from a 6-Month Randomized Controlled Trial
Abstract
Background/Objectives: In India, according to the National Family Health Survey (NFHS-5), 36% of children under five years old are stunted, 19% are wasted, and 32% are underweight, indicating widespread undernutrition. Methods: A randomized controlled trial was conducted between August 2023 and May 2024 (CTRI/2023/04/051566), enrolling 223 undernourished Indian children, randomly assigned to the oral nutritional supplement (ONS) + dietary counseling (DC) (n = 111) arm or the dietary counseling (DC) arm (n = 112). This study recruited both male and female subjects with picky eating habits and with height-for-age (HAP) and weight-for-height percentiles (WHP) below the 25th percentile according to the WHO Growth Standards and Growth Reference. Outcomes assessed were anthropometric indices, dietary intake, sick days, and nutrient adequacy. Data were analyzed using ANCOVA, with statistical significance at p < 0.05. Results: At 6 months, the ONS + DC group showed significant improvements compared to DC in HAP (12.1 vs. −0.4, LS Mean difference [95% CI], 13.3 [11.13, 15.48], p < 0.0001), and WAP (9.7 vs. 2.3, LS Mean difference [95% CI] 7.9 [5.07, 10.78], p < 0.0001). MUACP significantly increased in the ONS + DC group (11.1 vs. −1.0 in DC, LS Mean difference [95% CI], 11.1 [5.28, 16.99], p < 0.0001). Dietary intake of carbohydrates, proteins, and energy was significantly higher in the ONS + DC group at 3 months, with sustained improvements at 6 months. By 6 months, the ONS + DC…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 223 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.